Core Viewpoint - Orion Energy Systems, Inc. will present at the Emerging Growth Conference on February 25-26, 2026, showcasing its energy-efficient solutions and providing an opportunity for real-time interaction with investors and analysts [1][2]. Company Overview - Orion Energy Systems specializes in energy efficiency and clean technology solutions, including LED lighting, electric vehicle (EV) charging stations, and maintenance services [7]. - The company focuses on turnkey design-through-installation solutions for large national customers and projects through ESCO and distribution partners, aiming to help customers achieve business and environmental goals [7]. Conference Details - The presentation will be led by CEO Sally Washlow and CFO Per Brodin, lasting 30 minutes, starting at 12:35 p.m. ET on February 26, 2026 [2]. - Attendees can submit questions in advance and during the event, with the aim of addressing as many inquiries as possible [3]. - An archived webcast will be available for those unable to attend the live event [4]. Conference Significance - The Emerging Growth Conference serves as a platform for public companies to present new products and services to the investment community efficiently [5]. - The conference covers a wide range of growth sectors and attracts a large audience, including individual and institutional investors, advisors, and analysts [6].

Core Insights - Silo Pharma, Inc. has received a Notice of Allowance from the Japan Patent Office for a patent application related to its lead asset, SPC-15, which targets Post-Traumatic Stress Disorder (PTSD) [1][2][3] - The patent application is titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," enhancing Silo's intellectual property portfolio in stress-modulating therapeutics [2][3] - The approval of the patent is significant for Silo as it protects its lead asset and reinforces the novelty of its approach to preventing stress-induced behavioral disorders [3] Company Overview - Silo Pharma is a developmental-stage biopharmaceutical company focused on innovative formulations and drug delivery systems for traditional therapeutics and psychedelic treatments [1][4] - The company addresses underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, with a portfolio that includes SPC-15 for PTSD and SP-26 for fibromyalgia and chronic pain [4] - Silo conducts research in collaboration with leading universities and laboratories, indicating a strong foundation for its therapeutic developments [4]

Not for distribution to United States newswire services or for release, publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Latin Metals Inc. ("Latin Metals") (TSXV: LMS, OTCQB: LMSQF) and Latin Explore Inc. ("Latin Explore"), updates that the previously announced spin-out transaction (the "Spin-Out") of Latin Metals’ Para Copper Project (the "Para Project") and Auquis Copper Pro ...

Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter; treated 35 subjects to date with another 11 identified Continued absence of cardiotoxicity and high efficacy expected to position Annamycin as a “significant advancement” in AML treatment HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nas ...

Core Insights - Biomerica, Inc. has received approval from Vietnam's Hanoi Department of Health for its EZ Detect™ colorectal disease at-home screening test, marking a significant step in the company's global expansion into Southeast Asia [1][2][11] Group 1: Product Overview - EZ Detect™ is an FDA-cleared two-minute at-home screening test designed to detect early warning signs of colorectal cancer and other colorectal diseases [2][7] - The test identifies occult blood in stool, which is a critical early indicator of colorectal diseases, including cancer [8] - The test is user-friendly, requiring no special preparation or handling of stool, and can be completed privately at home [8][9] Group 2: Market Opportunity - Colorectal cancer is a significant public health issue in Vietnam, with 16,835 new cases reported in 2022, making it the fourth most common cancer in the country [3] - The five-year survival rate for colorectal cancer in Vietnam is only 45%, compared to 91% in the United States when detected early [3][10] - The global market for colorectal cancer screening is substantial, with approximately 1.93 million new cases and over 900,000 deaths worldwide in 2022, and these figures are expected to rise significantly by 2050 [5] Group 3: Strategic Importance - The approval of EZ Detect™ represents a milestone for Biomerica's strategic entry into Southeast Asia's rapidly growing healthcare market, which has over 680 million people and increasing healthcare spending [2][11] - The company aims to work with a major healthcare distributor in Vietnam to ensure widespread availability of the product through various sales channels [1][11] - This approval serves as a template for potential expansion into other Southeast Asian markets, emphasizing the importance of accessible at-home screening tests [11]

MAYFIELD VILLAGE, OHIO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended January 31, 2026: January(millions, except per share amounts and ratios; unaudited)2026 2025 ChangeNet premiums written$6,735 $6,481 4 <td ...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA Allied’s base shelf prospectus and the shelf prospectus supplement for the public offering are accessible through SEDAR+ TORONTO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Allied Properties Real Estate Investment Trust (“Allied”) (TSX:AP.UN) announced today that it has closed its previously announced marketed public offering (the “Public Offering”) and concurrent private placement (the “Private Placement”) of units o ...

Core Viewpoint - Allarity Therapeutics has initiated a Phase 2 clinical trial for stenoparib in combination with temozolomide for the treatment of relapsed small cell lung cancer (SCLC), with the first patients already dosed [1][4]. Group 1: Clinical Trial Details - The trial is funded by the U.S. Department of Veterans Affairs (VA) and is being conducted across 11 VA medical centers in the United States [2][8]. - Patient recruitment is ongoing, reflecting a significant unmet medical need in relapsed SCLC [4][5]. Group 2: Mechanism of Action - Stenoparib is a dual inhibitor targeting both PARP and the WNT pathway, which may enhance the effects of temozolomide while mitigating drug resistance associated with advanced cancers like relapsed SCLC [3][4]. - The drug's ability to cross the blood-brain barrier is particularly relevant for SCLC, where brain metastases are common [6]. Group 3: Safety and Efficacy - Stenoparib has shown a favorable safety profile compared to earlier-generation PARP inhibitors, which were limited by hematologic toxicity [4]. - The combination therapy aims to maximize tumor cell death while minimizing toxicity risks [4]. Group 4: Market Context - Over 218,000 Americans are diagnosed with lung cancer annually, with approximately 12% being SCLC, highlighting the need for effective treatment options [5]. - Real-world data indicates that only 40% of SCLC patients receive second-line treatment, with a median treatment duration of under two months [5]. Group 5: Company Overview - Allarity Therapeutics is focused on developing personalized cancer treatments, particularly stenoparib, and utilizes a drug response predictor (DRP) to identify patients likely to benefit from treatment [11]. - The company has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [7].

Core Insights - STRATA Skin Sciences, Inc. announces the addition of the XTRAC® 308 nm excimer laser to the clinical offerings of Johns Hopkins Dermatology, enhancing treatment options for chronic inflammatory and autoimmune skin diseases [1][2] Group 1: Company Overview - STRATA Skin Sciences is a medical technology company focused on developing and marketing innovative dermatologic treatments, including the XTRAC excimer laser, VTRAC lamp systems, and TheraClearX Acne Therapy System [5] - The company employs a unique Partnership Program that offers a fee per treatment cost structure, including on-site training, service, maintenance, and advertising support for practices [6] Group 2: Technology and Clinical Impact - The integration of XTRAC into Johns Hopkins' clinical programs supports advanced, targeted care for conditions like psoriasis, vitiligo, and atopic dermatitis, while also facilitating ongoing clinical research [2][3] - Excimer laser technology is backed by over 300 published peer-reviewed clinical studies, reinforcing its effectiveness in managing inflammatory skin conditions [4] Group 3: Academic Collaborations - STRATA collaborates with leading academic institutions, including New York University, University of California, and Cleveland Clinic, to promote evidence-based dermatologic care and expand access to FDA-cleared phototherapy [3]

Core Insights - Rackspace Technology and Palantir Technologies have formed a strategic partnership to enhance the deployment and operation of AI solutions for enterprises, focusing on measurable business outcomes [1][4] Partnership Overview - The partnership aims to enable customers to deploy AI use cases in production within weeks or months, significantly reducing the time compared to traditional methods [2][4] - Rackspace will provide a governed operating model that ensures consistent security, operating controls, and compliance, particularly for regulated industries [2][4] Implementation and Support - Organizations often struggle to derive value from AI due to a lack of in-house expertise; Rackspace will assist in prioritizing high-impact business problems and delivering implementation services [3][4] - Rackspace currently has 30 Palantir-trained engineers, with plans to scale this number to over 250 within the next year to support data migration and implementation [3] Customer Benefits - The partnership combines Rackspace's 25 years of experience in managing enterprise workloads with Palantir's decision-intelligence platform, offering a turnkey deployment model that reduces risk and operational burdens [4] - Customers can expect accelerated timelines for data migration, with Palantir AIP reducing completion times from years to days [5] Integrated Service Delivery - The collaboration aims to provide an end-to-end solution for deploying, governing, and operating AI across data environments, integrating infrastructure hosting, data migration, and ongoing managed operations [6]